Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Stock Information for Inhibrx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibrx Biosciences Inc.

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.